XML 82 R58.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

License, Acquisitions and Other Agreements - ALS Biopharma Agreement (Details) | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Aug. 31, 2015 prodrug claim | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($)
License and other agreements |  |  |  |  |
Milestone payment to be paid upon regulatory achievement |  | $ 641,975,000 |  | $ 641,975,000 |
Research and development |  | 314,819,000 | $ 79,490,000 | 470,791,000 | $ 142,951,000
ALS Biopharma Agreement | Collaborative arrangement |  |  |  |  |
License and other agreements |  |  |  |  |
Number of prodrugs of glutamate modulating agents | prodrug | 300 |  |  |  |
Milestone payment to be paid upon regulatory achievement |  | 4,000,000 |  | 4,000,000 |
Number of claims | claim | 1 |  |  |  |
Research and development |  | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Represents the amount of milestone payment to be paid by the company upon the achievement of specified regulatory milestones and annual royalty payments based on net sales of products from patents. + References No definition available. + Details
Name: | bhvn_MilestonePaymentToBePaidByCompanyUponSpecifiedRegulatoryMilestoneAchievement
Namespace Prefix: | bhvn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of claims if the Company abandons the sale of all products that will cause the reassignment of the applicable patent rights back to ALS Biopharma. + References No definition available. + Details
Name: | bhvn_NumberOfClaimsOfPatentsToReassign
Namespace Prefix: | bhvn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of prodrugs of glutamate modulating agents. + References No definition available. + Details
Name: | bhvn_NumberOfProdrugsOfGlutamateModulatingAgents
Namespace Prefix: | bhvn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=bhvn_ALSBiopharmaAndFoxChaseChemicalDiversityCenterIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |